Form 4: Avidity Biosciences Executive Receives Stock Options and Restricted Stock Units

Teresa McCarthy, Chief Human Resources Officer at Avidity Biosciences, was granted 50,000 stock options and 25,000 restricted stock units on January 6, 2025.

Summary

• Teresa McCarthy, the Chief Human Resources Officer of Avidity Biosciences, received 25,000 restricted stock units (RSUs) and 50,000 stock options on January 6, 2025.
• The RSUs vest in four equal installments annually starting January 6, 2026, contingent on continued service.
• The stock options vest monthly over four years, becoming fully vested on January 6, 2029.
• The exercise price for the stock options is $31.42.
• Following these transactions, Ms. McCarthy beneficially owns 107,867 shares of common stock.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally positive for aligning management with shareholder interests. There are no negative aspects to the document.

Positives

• The granting of stock options and RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.
• The grants are a form of compensation and incentive for the executive.

Risks

• The value of the stock options and RSUs is dependent on the future performance of Avidity Biosciences' stock price.
• If the executive leaves the company before the vesting dates, they may forfeit some or all of the unvested options and RSUs.

Future Outlook

The document does not contain any forward-looking statements or guidance.

Industry Context

This is a standard practice for publicly traded companies to grant stock options and restricted stock units to executives as part of their compensation packages. This aligns the executive's interests with the company's performance and shareholder value.

Comparison to Industry Standards

• Granting stock options and RSUs to executives is a common practice in the biotechnology industry, similar to companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals.
• The vesting schedules are also typical, with RSUs vesting over a few years and stock options vesting over a longer period to incentivize long-term performance.
• The specific amounts and exercise prices are company-specific and depend on the executive's role and the company's valuation.

Stakeholder Impact

• Shareholders may view this as a positive sign that the company is incentivizing its executives.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

stock options, restricted stock units, RSUs, executive compensation, insider trading, Avidity Biosciences, RNA, Teresa McCarthy